S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Most profitable less than $5 stock in the world? (Ad)pixel
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
NASDAQ:FATE

Fate Therapeutics - FATE Price Target & Analyst Ratings

$33.82
+1.17 (+3.58%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$32.85
$35.19
50-Day Range
$17.78
$34.14
52-Week Range
$17.10
$91.90
Volume
1.42 million shs
Average Volume
1.47 million shs
Market Capitalization
$3.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.42

Fate Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$75.42
122.99% Upside
High Prediction$115.00
Average Prediction$75.42
Low Prediction$28.00
TypeCurrent
8/13/21 to 8/13/22
1 Month Ago
7/14/21 to 7/14/22
3 Months Ago
5/15/21 to 5/15/22
1 Year Ago
8/13/20 to 8/13/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
11 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$75.42$74.09$87.22$113.13
Predicted Upside122.99% Upside73.69% Upside58.39% Upside20.59% Upside
Get Fate Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.


FATE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FATE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fate Therapeutics Stock vs. The Competition

TypeFate TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside122.99% Upside724.39% Upside13.81% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
466
74.09%
Underperform Votes
163
25.91%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/4/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$135.00 ➝ $90.00+174.31%
7/28/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
7/11/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$50.00 ➝ $47.00+56.61%
6/2/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$28.00+19.86%
5/23/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$113.00 ➝ $71.00+207.36%
4/13/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $75.00+103.03%
4/1/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Watsek
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
3/4/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robert Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$122.00 ➝ $115.00+247.96%
3/1/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Nierengarten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$74.00 ➝ $77.00+123.71%
1/3/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$107.00 ➝ $78.00+31.96%
12/15/2021Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$74.00 ➝ $62.00+23.88%
12/7/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/8/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$94.00 ➝ $87.00+42.90%
11/8/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$118.00 ➝ $115.00+87.24%
11/5/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$90.00 ➝ $60.00-3.63%
7/9/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Benjamin Burnett
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$116.00+28.25%
4/26/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$145.00+57.93%
3/4/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$84.00 ➝ $130.00+46.91%
2/26/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$115.00+33.30%
2/25/2021Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$88.00 ➝ $109.00+14.41%
1/15/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Overweight$110.00 ➝ $130.00+10.73%
12/7/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$63.00 ➝ $76.00+25.02%
3/3/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$27.00 ➝ $42.00+48.67%
11/12/2019SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+72.41%
9/16/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$30.00 ➝ $28.00+56.16%
(Data available from 8/13/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












FATE Price Target - Frequently Asked Questions

What is Fate Therapeutics's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Fate Therapeutics stock is Moderate Buy based on the current 4 hold ratings and 8 buy ratings for FATE. The average twelve-month price prediction for Fate Therapeutics is $75.42 with a high price target of $115.00 and a low price target of $28.00. Learn more on FATE's analyst rating history.

Do Wall Street analysts like Fate Therapeutics more than its competitors?

Analysts like Fate Therapeutics less than other Medical companies. The consensus rating for Fate Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how FATE compares to other companies.

Do MarketBeat users like Fate Therapeutics more than its competitors?

MarketBeat users like Fate Therapeutics more than other Medical companies. 74.09% of MarketBeat users gave Fate Therapeutics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is Fate Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Fate Therapeutics's stock had 1 upgrade by analysts.

Does Fate Therapeutics's stock price have much upside?

According to analysts, Fate Therapeutics's stock has a predicted upside of 78.76% based on their 12-month price targets.

What analysts cover Fate Therapeutics?

Fate Therapeutics has been rated by BMO Capital Markets, Needham & Company LLC, Oppenheimer, Piper Sandler, and Robert W. Baird in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:FATE) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.